Brief: U.S. FDA Approves SECUADO Transdermal System, The First-And-Only Transdermal Patch For The Treatment Of Adults With Schizophrenia

Hisamitsu Pharmaceutical Co

15/10/2019 14:24

Oct 15 (Reuters) - Hisamitsu Pharmaceutical Co Inc  4530.T :
    * U.S. FDA APPROVES SECUADO® (ASENAPINE) TRANSDERMAL SYSTEM,
THE
FIRST-AND-ONLY TRANSDERMAL PATCH FOR THE TREATMENT OF ADULTS
WITH SCHIZOPHRENIA
    * NOVEN PHARMACEUTICALS, UNIT OF HISAMITSU PHARMACEUTICAL,
SAYS
FDA HAS APPROVED SECUADO TRANSDERMAL SYSTEM FOR TREATMENT OF
ADULTS WITH SCHIZOPHRENIA

Source text for Eikon:  ID:nBw13CrhJa 
Further company coverage:  4530.T 

 ((Reuters.Briefs@thomsonreuters.com;))